Immunoglobulin G and immunoglobulin A anti-Ro52 in plasma and saliva show little association with disease activity in patients with primary Sjögren’s disease
Open Access
- 6 May 2026
- journal article
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (5) , 1-9
Abstract
Primary Sjögren's disease (pSjD) is one of the most common autoimmune connective tissue diseases. Sicca symptoms are a hallmark of pSjD. Up to 80% of patients have immunoglobulin G (IgG) anti-Ro52 autoantibodies in their plasma. This study investigates the frequency of IgG and IgA anti-Ro52 autoantibodies in plasma and saliva from pSjD patients, and assess the associations between disease activity and autoantibody titers. The study was conducted on a Norwegian cross-sectional SjD cohort (n = 113). IgA and IgG anti-Ro52 autoantibodies were measured in plasma and saliva by an indirect in-house enzyme-linked immunosorbent assay (ELISA). ELISA results were correlated with clinical data using relative risk and Spearman's correlation coefficients. Measuring plasma, 73% of the cohort were positive for IgG anti-Ro52 and 47% for IgA anti-Ro52 autoantibodies. In saliva, 34% were positive for IgA anti-Ro52 and 17% for IgG anti-Ro52 autoantibodies. We observed an inverse correlation between plasma IgG anti-Ro52 autoantibodies and disease activity. Patients with a low plasma titre of IgG anti-Ro52 autoantibodies had a higher probability of reporting pain, as indicated by the EULAR Sjögren's Syndrome Patient Reported Index score (relative risk = 0.48, 95% confidence interval 0.29-0.80, p = 0.002). Furthermore, plasma IgA anti-Ro52 correlated significantly with the focus score. IgA and IgG anti-Ro52 autoantibodies in saliva and plasma showed an inverse correlation with disease activity but significant positive association with immune activity in patients with SjD. Our findings do not support the use of salivary IgA and IgG anti-Ro52 autoantibodies as biomarkers of disease activity in SjD.Keywords
Funding Information
- Danish Rheumatoid Association, Aarhus University Research Foundation (AUFF-E-2016-9-27)
- Gilead Nordic Fellowship (DFF-4285)
- Grosserer L. F. Foghts Fond (22.057)
- Aase og Ejnar Danielsens Fond (23-10-0290)
This publication has 22 references indexed in Scilit:
- Differences in Dynamics of Specific Antinuclear Antibodies and Their Susceptibility to B Cell–Targeting Treatment in Patients With Systemic Lupus ErythematosusArthritis & Rheumatology, 2025
- Seronegative patients with primary Sjögren's syndrome and non-pSS sicca test positive for anti-SSA/Ro52 and -Ro60 in salivaBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2024
- Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohortsThe Lancet Rheumatology, 2024
- Association of Combined Anti‐Ro52/TRIM21 and Anti‐Ro60/SSA Antibodies With Increased Sjögren Disease Severity Through Interferon Pathway ActivationArthritis & Rheumatology, 2024
- Ro52/TRIM21 – From host defense to autoimmunityCellular Immunology, 2023
- An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical managementAutoimmunity Reviews, 2022
- Antibodies to Both Ro52 and Ro60 for Identifying Sjögren's Syndrome Patients Best Suited for Clinical Trials of Disease‐Modifying TherapiesArthritis Care & Research, 2021
- 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data‐Driven Methodology Involving Three International Patient CohortsArthritis & Rheumatology, 2016
- Sjögren syndromeNature Reviews Disease Primers, 2016
- The immunobiology of Ro52 (TRIM21) in autoimmunity: A critical reviewJournal of Autoimmunity, 2012